САХАРНЫЙ ДИАБЕТ И ИНФЕКЦИЯ COVID-19: КЛИНИЧЕСКИЙ АНАЛИЗ И ЭФФЕКТИВНОСТЬ ЛЕЧЕНИЯ НА ПРИМЕРЕ ТАШКЕНТА
##article.subject##:
қандли диабет, COVID-19, метформин, инсулин, ДПП4, сульфонилмочевина##article.abstract##
COVID-19 пандемияси бошланиши билан олимлар ушбу инфекция ва унинг асоратларини келтириб чиқарувчи патогенетик механизмларни аниқлашга, сурункали касалликлар билан оғриган беморлар гуруҳларини таҳлил қилишга ва инфекция ҳамда унинг ўткир ва сурункали асоратларига қарши самарали кураш усулларини ишлаб чиқишга киришдилар. Тадқиқотда 2020 йил апрелдан декабргача бўлган даврда COVID-19 инфекциясини ўтказган 5023 нафар бемор маълумотлари таҳлил қилинди. Беморлар тўрт гуруҳга бўлинди: қандли диабети йўқ (3648 киши), 1-тур ҚД (213 киши), 2-тур ҚД (763 киши) ва COVID-19 пайтида янги аниқланган ҚД (399 киши). Тадқиқот натижалари шуни кўрсати, қандли диабет айниқса 2-тури билан оғриган , беморларда нафас қисилиши, кўкрак оғриғи ва аритмия каби клиник аломатлар кучлироқ намоён бўлган. Сульфонилмочевина қабул қилган беморлар нафас қисилишига кўпроқ шикоят қилган.
Библиографические ссылки
Wu C, Chen X, Cai Y, et al. Risk Factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. doi: https://doi.org/10.1001/jamainternmed.2020.0994 10. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211-212. doi: https
Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metabol. 2012;16(S1):S27-S36. doi: https://doi.org/10.4103/2230-8210.94253
Peleg Y, Weerarathna T, McCarthy JS, Davis T. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23(1):3-13. doi: https://doi.org/10.1002/dmrr.682
Alieva AV, Ismailov SI, Rahimova GN. Epidemiology of diabetes and prediabetes in Uzbekistan: Screening results. Health Sci J. 2018;12(6):609. doi: https://doi.org/10.21767/1791-809X.1000609
Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;36(7). doi: https://doi.org/10.1002/dmrr.3319
Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;(55):2000547.
Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi: https://doi.org/10.1016/S2213-8587(20)30272-2
Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823-833. doi: https://doi.org/10.1016/S2213-8587(20)30271-0
Singh AK, Singh R, Saboo B, Misra A. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A critical appraisal of literature. Diabetes Metab Syndr Clin Res Rev. 2021;15(1):159-167. doi: https://doi.org/10.1016/j.dsx.2020.12.026
